1. FluBlok (Seasonal Influenza Vaccines) Forecast and Market
Analysis
Report Details:
Published:November 2012
No. of Pages: 68
Price: Single User License – US$6995
FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, FluBlok (Seasonal
Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection
caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough.
The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection.
Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip,
GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the
market. However, with the entrance of vaccines with novel routes of administration, such as
AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a
dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines.
GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal
market share, patient share, and revenue from the trivalent influenza vaccines currently available.
FluBlok is being developed by the Protein Sciences Corporation (PSC), headquartered in Meriden,
Connecticut in the US. FluBlok is the leading vaccine candidate in PSC’s vaccine portfolio that
also focuses on pandemic influenza, SARS and flu vaccine adjuvants. The trivalent vaccine
consists of recombinant hemagglutinin protein, from H1, H3 and B strains, that are propagated in a
baculovirus expression vector system in insect cells (FDA Briefing document). The vaccine is a
first-in-class product that is the first vaccine to use an insect cell-based manufacturing system in
the US.
Scope
- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on FluBlok including product description, safety and efficacy profiles as well
as a SWOT analysis.

2. - Sales forecast for FluBlok in the US from 2011 to 2022.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for
seasonal Influenza.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of FluBlok
performance
- Obtain sales forecast for Tabalumab from 2011 to 2022 in (the US, France, Germany, the UK,
Italy, Spain, Japan and Australia)
Get your copy of this report @
http://www.reportsnreports.com/reports/213203-flublok-seasonal-influenza-vaccines-forecast-and-market-
analysis.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
3 Disease Overview 9
3.1 Etiology and Pathophysiology 9
3.1.1 Etiology 9
3.1.2 Pathophysiology 13
3.2 Symptoms 14
3.3 Prognosis 14
4 Disease Management 15
4.1 Influenza Vaccination Policy 15
5 Competitive Assessment 17
5.1 Overview 17
5.2 Strategic Competitor Assessment 17
6 Opportunity and Unmet Need 20
6.1 Overview 20
6.2 Unmet Needs 21
6.2.1 Higher level of patient awareness 21
6.2.2 Increased efficacy in the elderly and young children (6.2.3 Improved vaccine side-effect
profiles 22

3. 6.2.4 More efficient vaccine manufacturing process 22
6.2.5 More cost-effective vaccines 23
6.3 Gap Analysis 24
6.4 Opportunities 25
6.4.1 Expanded breadth of protection against viral strains 25
6.4.2 Increased duration of protection 26
6.4.3 T-cell involvement 26
7 Pipeline Assessment 27
7.1 Overview 27
7.2 Promising vaccines in clinical development 28
7.2.1 FluBlok 30
8 Appendix 38
8.1 Bibliography 38
8.2 Abbreviations 57
8.3 Methodology 59
8.4 Forecasting Methodology 59
8.4.1 Vaccine Coverage 60
8.4.2 Vaccines Included 60
8.4.3 Key Launch Dates 61
8.4.4 Influenza Vaccine Tender System Assumptions 62
8.4.5 General Pricing Assumptions 62
8.4.6 Pricing of Pipeline Agents 63
8.5 Physicians and Specialists Included in this Study 63
8.6 Primary Research - Prescriber Survey 64
8.7 About the Authors 65
8.7.1 Authors 65
8.7.2 Epidemiologists 66
8.7.3 Global Head of Healthcare 67
8.8 About GlobalData 68
8.9 Contact Us 68
8.10 Disclaimer 68
1.1 List of Tables
Table 1: Notable Influenza Pandemics 13
Table 2: Symptoms of Influenza 14
Table 3: Influenza Vaccination Recommendation Committees by Country 15
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012 16
Table 5: Leading Influenza Vaccines, 2012 19
Table 6: Overall Unmet Needs - Current Level of Attainment 20
Table 7: Clinical Unmet Needs - Gap Analysis, 2012 24
Table 8: Seasonal Influenza Vaccines - Phase Pipeline, 2012 28
Table 9: Product Profile - FluBlok 31

4. Table 10: FluBlok SWOT Analysis, 2012 36
Table 11: Global Sales Forecasts ($m) for FluBlok, 2012-2022 37
Table 12: Key Launch Dates 61
Table 13: Physicians Surveyed, By Country 64
1.2 List of Figures
Figure 1: Influenza Virus Structure 9
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-
2022 29
Contact: sales@reportsandreports.com for more information.